EDITORIAL
“Weight-ing” for an answer on optimal valganciclovir prophylaxis dosing in pediatric solid organ transplantation recipients
This article relates to:
-
Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis
- Rochelle Liverman,
- Anastacia Serluco,
- Gwen Nance,
- Roshan George,
- Dellys Soler Rodriguez,
- Shriprasad Deshpande,
- Chad Mao,
- Rouba Garro,
- Inci Yildirim,
- Volume 27Issue 4Pediatric Transplantation
- First Published online: March 21, 2023
D. E. Dulek,
M. I. Ardura,
D. E. Dulek
Department of Pediatrics, Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Tennessee, Nashville, USA
Search for more papers by this authorCorresponding Author
M. I. Ardura
Department of Pediatrics, Division of Infectious Diseases & Host Defense, Nationwide Children's Hospital & The Ohio State University College of Medicine, Ohio, Columbus, USA
Correspondence
M. I. Ardura, Department of Pediatrics, Division of Infectious Diseases & Host Defense, Nationwide Children's Hospital & The Ohio State University of College of Medicine, 700 Children's Drive, Columbus, Ohio 43205, USA.
Email: [email protected]
Search for more papers by this authorD. E. Dulek,
M. I. Ardura,
D. E. Dulek
Department of Pediatrics, Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Tennessee, Nashville, USA
Search for more papers by this authorCorresponding Author
M. I. Ardura
Department of Pediatrics, Division of Infectious Diseases & Host Defense, Nationwide Children's Hospital & The Ohio State University College of Medicine, Ohio, Columbus, USA
Correspondence
M. I. Ardura, Department of Pediatrics, Division of Infectious Diseases & Host Defense, Nationwide Children's Hospital & The Ohio State University of College of Medicine, 700 Children's Drive, Columbus, Ohio 43205, USA.
Email: [email protected]
Search for more papers by this author
Open Research
DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
REFERENCES
- 1Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-guidelines of the American Society of Transplantation infectious diseases Community of Practice. Clin Transplant. 2019; 33:e13512.
- 2Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021; 19: 759-773.
- 3Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the Management of Cytomegalovirus in solid-organ transplantation. Transplantation. 2018; 102: 900-931.
- 4 Valcyte Prescribing Information. Genentech 2021.
- 5Hayes M, Boge CLK, Sharova A, et al. Antiviral toxicities in pediatric solid organ transplant recipients. Am J Transplant. 2022; 22: 3012-3020.
- 6Jorga K, Reigner B, Chavanne C, Alvaro G, Frey N. Pediatric dosing of ganciclovir and valganciclovir: how model-based simulations can prevent underexposure and potential treatment failure. CPT Pharmacometrics Syst Pharmacol. 2019; 8: 167-176.
- 7Asberg A, Bjerre A, Neely M. New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients. Pediatr Transplant. 2014; 18: 103-111.
- 8Bradley D, Moreira S, Subramoney V, et al. Pharmacokinetics and safety of valganciclovir in pediatric heart transplant recipients 4 months of age and younger. Pediatr Infect Dis J. 2016; 35: 1324-1328.
- 9Vaudry W, Ettenger R, Jara P, et al. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant. 2009; 9: 636-643.
- 10Villeneuve D, Brothers A, Harvey E, et al. Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients. Pediatr Transplant. 2013; 17: 80-85.
- 11Yu MA, Park JM. Valganciclovir: therapeutic role in pediatric solid organ transplant recipients. Expert Opin Pharmacother. 2013; 14: 807-815.
- 12Pescovitz MD, Ettenger RB, Strife CF, et al. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Transpl Infect Dis. 2010; 12: 195-203.
- 13Thomas AN, Nguyen PB, Miller JL, Neely SB, Lewis TV. Incidence of cytomegalovirus DNAemia in pediatric post-renal transplant patients receiving weight-based vs body surface area-based valganciclovir chemoprophylaxis. J Pediatr Pharmacol Ther. 2022; 27: 164-171.
- 14Stockmann C, Roberts JK, Knackstedt ED, Spigarelli MG, Sherwin CM. Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection. Expert Opin Drug Metab Toxicol. 2015; 11: 205-219.
- 15Shaikh S, Jasiak-Panek N, Park JM. A national survey of valganciclovir dosing strategies in pediatric organ transplant recipients. Clin Transplant. 2018; 32:e13369.
- 16Kimberlin DW, Acosta EP, Sanchez PJ, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis. 2008; 197: 836-845.
- 17 FDA Drug Safety Communication: New dosing recommendations to prevent potential Valcyte (valganciclovir) overdose in pediatric transplant patients. Accessed November 20, 2022, at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-dosing-recommendations-prevent-potential-valcyte-valganciclovir
- 18Peled O, Berkovitch M, Rom E, et al. Valganciclovir dosing for cytomegalovirus prophylaxis in pediatric solid-organ transplant recipients: a prospective pharmacokinetic study. Pediatr Infect Dis J. 2017; 36: 745-750.
- 19Facchin A, Elie V, Benyoub N, et al. Population pharmacokinetics of ganciclovir after valganciclovir in renal transplant children. Antimicrob Agents Chemother. 2019; 63: 1-10.
- 20Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation. 2005; 79: 1477-1483.
- 21Camacho-Gonzalez AF, Gutman J, Hymes LC, Leong T, Hilinski JA. 24 weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience. Transplantation. 2011; 91: 245-250.
- 22Hashim F, Gregg JA, Dharnidharka VR. Efficacy of extended valganciclovir prophylaxis in preventing cytomegalovirus infection in pediatric kidney transplantation. Open Urol Nephrol J. 2014; 7: 152-157.
- 23Das BB, Prusty BK, Niu J, Sue PK. Cytomegalovirus infection and allograft rejection among pediatric heart transplant recipients in the era of valganciclovir prophylaxis. Pediatr Transplant. 2020; 24:e13750.
- 24Pappo A, Peled O, Berkovitch M, et al. Efficacy and safety of a weight-based dosing regimen of valganciclovir for cytomegalovirus prophylaxis in pediatric solid-organ transplant recipients. Transplantation. 2019; 103: 1730-1735.
- 25Hocker B, Zencke S, Krupka K, et al. Cytomegalovirus infection in pediatric renal transplantation and the impact of chemoprophylaxis with (Val-)ganciclovir. Transplantation. 2016; 100: 862-870.
- 26Suresh S, Lee BE, Robinson JL, Akinwumi MS, Preiksaitis JK. A risk-stratified approach to cytomegalovirus prevention in pediatric solid organ transplant recipients. Pediatr Transplant. 2016; 20: 970-980.
- 27Mehta K, Al-Yabes O, Allen A, et al. Burden of cytomegalovirus DNAemia among pediatric renal transplant patients on antiviral prophylaxis: a hospital-based analysis. Pediatr Transplant. 2020; 24:e13650.
- 28Cameron BM, Kennedy SE, Rawlinson WD, Mackie FE. The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children. Pediatr Transplant. 2017; 21:e12816.
- 29Varela-Fascinetto G, Benchimol C, Reyes-Acevedo R, et al. Tolerability of up to 200 days of prophylaxis with valganciclovir oral solution and/or film-coated tablets in pediatric kidney transplant recipients at risk of cytomegalovirus disease. Pediatr Transplant. 2017; 21:e12833.
- 30Paulsen G, Cumagun P, Mixon E, Fowler K, Feig D, Shimamura M. Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal valganciclovir prophylaxis. Pediatr Transplant. 2019; 23:e13382.
- 31Ganapathi L, Blumenthal J, Alawdah L, et al. Impact of standardized protocols for cytomegalovirus disease prevention in pediatric solid organ transplant recipients. Pediatr Transplant. 2019; 23:e13568.
- 32Pangonis S, Paulsen G, Andersen H, et al. Evaluation of a change in cytomegalovirus prevention strategy following pediatric solid organ transplantation. Transpl Infect Dis. 2020; 22:e13232.
- 33Lin A, Worley S, Brubaker J, et al. Assessment of cytomegalovirus hybrid preventative strategy in pediatric heart transplant patients. J Pediatric Infect Dis Soc. 2012; 1: 278-283.
- 34Valencia Deray KG, Hosek KE, Chilukuri D, et al. Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients. Am J Transplant. 2022; 22: 187-198.
- 35Downes KJ, Sharova A, Boge CLK, et al. CMV infection and management among pediatric solid organ transplant recipients. Pediatr Transplant. 2022; 26:e14220.
Citing Literature
